This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (49)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jørgen Jeppesen, MD; Hans Ole Hein, MD; Poul Suadicani, DD; Finn Gyntelberg, MD

Arch Intern Med. 2001;161:361-366.

Background  A high triglyceride (TG)–low high-density lipoprotein cholesterol (HDL-C) level (TG 1.60 mmol/L [142 mg/dL] and HDL-C 1.18 mmol/L [46 mg/dL]) is associated with a high risk of ischemic heart disease (IHD), whereas a low TG–high HDL-C level (TG 1.09 [97 mg/dL] and HDL-C 1.48 mmol/L [57 mg/dL]) is associated with a low risk. Conventional risk factors tend to coexist with high TG–low HDL-C levels. We tested the hypothesis that subjects with conventional risk factors would still have a low risk of IHD if they had low TG–high HDL-C levels.

Methods  Observational cohort study of 2906 men aged 53 to 74 years free of IHD at baseline.

Results  During 8 years, 229 subjects developed IHD. Stratified by conventional risk factors—low-density lipoprotein cholesterol level (4.40 mmol/L or >4.40 mmol/L [170 mg/dL or >170 mg/dL] [median value]), hypertensive status (blood pressure >150/100 mm Hg or taking medication), level of physical activity (>4 h/wk or 4 h/wk), and smoking status (nonsmokers vs smokers)—the incidence in men with high TG–low HDL-C levels was 9.8% to 12.2% in the low-risk and 12.2% to 16.4% in the high-risk strata; the corresponding values in men with low TG–high HDL-C concentrations were 4.0% to 5.1% and 3.7% to 5.3%, respectively. Based on an estimate of attributable risk, 35% of IHD might have been prevented if all subjects had had low TG–high HDL-C levels.

Conclusion  Men with conventional risk factors for IHD have a low risk of IHD if they have low TG–high HDL-C levels.

From The Copenhagen Male Study, Epidemiological Research Unit, Copenhagen University Hospital, Bispebjerg (Drs Jeppesen, Hein, Suadicani, and Gyntelberg), and The Glostrup Population Studies, Department of Internal Medicine C, Glostrup University Hospital, Glostrup (Dr Hein), Denmark.

Corresponding author and reprints: Jørgen Jeppesen, MD, The Copenhagen Male Study, Epidemiological Research Unit, Copenhagen University Hospital, Bispebjerg, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(3):487-488.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Individual Components of the Metabolic Syndrome: Is There a Raison d'Etre?
Reaven
J. Am. Coll. Nutr. 2007;26:191-195.
FULL TEXT  

Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease
Bloomgarden
Diabetes Care 2006;29:1973-1980.
FULL TEXT  

Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study
Koh et al.
Eur Heart J 2005;26:1362-1368.
ABSTRACT | FULL TEXT  

The metabolic syndrome: one step forward, two steps back
Kim and Reaven
Diabetes and Vascular Disease Research 2004;1:68-75.
ABSTRACT  

Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method
Hirano et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:558-563.
ABSTRACT | FULL TEXT  

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant
McLaughlin et al.
ANN INTERN MED 2003;139:802-809.
ABSTRACT | FULL TEXT  

Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Koh et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:1889-1894.
ABSTRACT | FULL TEXT  

Insulin resistance and compensatory hyperinsulinemia: The key player between cigarette smoking and cardiovascular disease?
Reaven and Tsao
J Am Coll Cardiol 2003;41:1044-1047.
ABSTRACT | FULL TEXT  

Importance of Identifying the Overweight Patient Who Will Benefit the Most by Losing Weight
Reaven
ANN INTERN MED 2003;138:420-423.
ABSTRACT | FULL TEXT  

Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease
Reaven
Circulation 2002;106:286-288.
FULL TEXT  

Updated Guidelines for Cholesterol Management
Lauer and Fontanarosa
JAMA 2001;285:2508-2509.
FULL TEXT  

HDL Cholesterol and Triglycerides for Predicting CAD Risk
JWatch General 2001;2001:1-1.
FULL TEXT